You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

58 search results for: asthma

How Can Biologics Improve Lung Function in Pediatric Severe <b>Asthma</b>?

expert video

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?

20 min

Pulmonology

Dr. Leonard Bacharier discusses the role of biologics in the improvement of lung function in pediatric severe asthma

ERS 2023 | Burden of Underlying Disease in Pediatric Severe <b>Asthma</b>

expert video

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

7 min

Pulmonology

Join pediatric asthma experts Prof. Giorgio Piacentini and Dr. Sharon Dell for an educational program on the topic of remission in pediatric asthma.

ERS 2023 | Progression of Underlying Disease in Pediatric Severe <b>Asthma</b>

expert video

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

10 min

Pulmonology

Join pediatric asthma experts Prof. Giorgio Piacentini and Dr. Sharon Dell for an educational program on the topic of remission in pediatric asthma.

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe <b>Asthma</b>

expert video

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

10 min

Pulmonology

Join pediatric asthma experts Prof. Giorgio Piacentini and Dr. Sharon Dell for an educational program on the topic of remission in pediatric asthma.

Eosinophils as a Biomarker for Type 2 <b>Asthma</b>

expert video

Eosinophils as a Biomarker for Type 2 Asthma

15 min

Pulmonology

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.

FeNO as a Biomarker for Type 2 <b>Asthma</b>

expert video

FeNO as a Biomarker for Type 2 Asthma

16 min

Pulmonology

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric <b>Asthma</b> in Children 6-11 Years of Age

interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

What is the Role of FeNO as an <b>Asthma</b> Biomarker?

expert video

What is the Role of FeNO as an Asthma Biomarker?

2 min

Pulmonology

Prof. Klaus Rabe and Dr. Michael Wechsler explore the utility of FeNO as a biomarker in asthma.

On-Treatment <b>Asthma</b> Remission: Moving Beyond Control

interactivity

On-Treatment Asthma Remission: Moving Beyond Control

5 min

Pulmonology

Learn about the proposed framework for clinical remission in patients with asthma

videoanimation

Asthma White Board Video

2 min

Pulmonology

Learn about type 2 inflammation in asthma, and the burden of asthma on patients and their families.

ERS 2023 | Pediatric <b>Asthma</b> Symposium: Patient Case Discussion

expert video

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

11 min

Pulmonology

Join pediatric asthma experts Prof. Giorgio Piacentini and Dr. Sharon Dell for an educational program on the topic of remission in pediatric asthma.

IgE as a Biomarker for Type 2 <b>Asthma</b>

expert video

IgE as a Biomarker for Type 2 Asthma

14 min

Pulmonology

Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustraliaChange country/region